PCNSL Clinical Trial
Official title:
Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed Primary Central Nervous System Large B-Cell Lymphoma Patients Intolerant to Haematopoietic Stem Cell Transplantation
This single-center, open, single-arm study aim to evaluate the efficacy and tolerability of a therapy introducing zanubrutinib on the basis of rituximab and methotrexate (MTX) [or temozolomide (TMZ), if intolerant to MTX] in treating patients newly diagnosed with primary CNS large B-cell lymphoma and intolerant to HSCT.
Status | Recruiting |
Enrollment | 29 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - 18 to 80 years old; - Histopathologically confirmed CD20 positive primary large B-cell lymphoma of the central nervous system (CNS) or primary vitreoretinal lymphoma according to the 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours [primary large B-cell lymphoma of the CNS previously named as primary diffuse large B-cell lymphoma (DLBCL) of the CNS in the revised 4th edition]; - Life expectancy of > 3 months (in the opinion of the investigator); - Creatinine Clearance Rate (CCR) = 50 mL/min or estimated Glomerular Filtration Rate (eGFR) = 60 mL/(minĀ·1.73 m^2); - International Normalized Ratio (INR) = 1.5 and activated Partial Thromboplastin Time (aPTT) = 1.5 times the upper limit of normal; - Left Ventricular Ejection Fraction (LVEF) = 50%; - Agreeing to provide written informed consent prior to any special examination or procedure for the research on their own or legal representative. Exclusion Criteria: - Pregnant or lactating women; - Known Hepatitis B Virus (HBV) and/or Hepatitis C Virus (HCV) infection (HBV infection refers to HBV-DNA > detectable limit); - With acquired or congenital immunodeficiency; - With congestive heart failure in 6 months before enrollment, New York Heart Association (NYHA) heart function class III or IV, or LVEF < 50%; - Known to be allergic to the test drug ingredients; - Diagnosed with or being treated for malignancy other than lymphoma; - With severe infection; - Substance abuse, medical, psychological, or social conditions that may interfere with the subjects' participation in the study or evaluation of the study results; - Deemed unsuitable for the group. |
Country | Name | City | State |
---|---|---|---|
China | Ruijin Hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Ruijin Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 2-year Progression-Free Survival | Progression-free survival was defined as the time from the date of first treatment until the date of the first documented day of disease progression or relapse, according to 2014 Lugano criteria, or death from any cause, whichever occurred first. | 2 years | |
Secondary | Overall Response Rate (ORR) | The ORR is defined as percentage of participants with overall response including complete response (CR), unconfirmed complete response (CRu) and partial response (PR), on the basis of investigator assessments, according to the 2005 Response Criteria of the International Primary CNS Lymphoma Collaborative Group (IPCG). | Baseline up to data cut-off (up to approximately 2 years) | |
Secondary | Complete Response (CR) Rate | The CR rate is defined as the proportion of patients with CR/CRu according to the 2005 Response Criteria of the International Primary CNS Lymphoma Collaborative Group (IPCG). | Baseline up to data cut-off (up to approximately 2 years) | |
Secondary | Overall Survival (OS) | Overall survival is defined as the time from the date of first treatment to the date of death from any cause. | Baseline up to data cut-off (up to approximately 2 years) | |
Secondary | Adverse Events | Any harmful reaction that occurs during the treatment of a disease according to the normal usage and dosage of a drug, which is unrelated to the purpose of treatment. | Baseline up to data cut-off (up to approximately 2 years) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05167630 -
Prognosis Factors in Patients With Primary Central Nervous System Lymphoma
|
||
Recruiting |
NCT04514393 -
Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma
|
Phase 2 | |
Recruiting |
NCT04481815 -
Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT04438044 -
A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL
|
Phase 2 | |
Active, not recruiting |
NCT03392714 -
Bendamustine-based Combination Therapy for PCNSL
|
Phase 2 | |
Not yet recruiting |
NCT05021770 -
Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05782374 -
Real World Data on Ibrutinib Use in PCNSL Rel/Ref
|